Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 19, Issue 1, 2002, Pages 73-98

  Schwendeman, Steven P ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antigen; Encapsulation; Poly(lactide co glycolide); Protein stability; Vaccine stability

Indexed keywords

ANTACID AGENT; ANTIGEN; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN; BOVINE SERUM ALBUMIN; COPOLYMER; EGG WHITE; ERYTHROPOIETIN; EXCIPIENT; GLYCOLIC ACID; GROWTH HORMONE; HUMAN GROWTH HORMONE; LACTIC ACID; PROTEIN; RIBONUCLEASE A; SOMATOMEDIN C; TETANUS TOXOID; VACCINE; VASCULOTROPIN; BIOMATERIAL; DRUG CARRIER; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; WATER;

BIODEGRADATION; COMPLEX FORMATION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; MICROCLIMATE; MOISTURE; PH; PROTEIN STABILITY; REVIEW; CHEMISTRY; DELAYED RELEASE FORMULATION; HUMAN; INJECTION;

BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG STABILITY; HUMAN; HYDROGEN-ION CONCENTRATION; INJECTIONS; LACTIC ACID; POLYGLYCOLIC ACID; POLYMERS; PROTEINS; SUPPORT, U.S. GOV'T, P.H.S.; WATER; HUMANS;

EID: 0036000111     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i1.20     Document Type: Review

References (112)

1. Protein stability in controlled-release systems
2. Stability of proteins and their delivery from biodegradable polymer microspheres
3. Improving protein therapeutics with sustained-release formulations
4. Protein instability in poly(lactic-co-glycolic acid) microparticles
5. Injectable biodegradable microspheres for vaccine delivery
6. Formulation and delivery of proteins and peptides design and development strategies
7. Progress and challenges for peptide, protein, and vaccine delivery from implantable polymeric systems
8. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines
9. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: Release kinetics and stability issues
10. Formulation and aerosol delivery of recombinant deoxyribonucleic acid derived human deoxyribonuclease. I
11. Parenteral delivery of peptide and protein drugs
12. Inhaled insulin
13. Transdermal and transmucosal powdered drug delivery
14. A month-long effect from a single injection of microencapsulated human growth hormone
15. Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide)
16. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: Serum drug level profiles and pharmacological effects in animals
17. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers
18. Discover and development of goserelin (Zoladex)
19. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate
20. A Booster Shot for Children's Vaccines
21. Potential of polymer microencapsulation technology for vaccine innovation
22. Controlled release vaccines-biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles
23. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide
24. Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique
25. Protein behavior at the water/methylene chloride interface
26. Protein denaturation by combined effect of shear and air-liquid interface
27. Protein spray-freeze drying: Effect of atomization conditions on particle size and stability
28. Mechanism of insulin aggregation and stabilization in agitated aqueous solutions
29. Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulatlon in biodegradable microspheres
30. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide
31. Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant
32. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers
33. Lyophilization-induced changes in the secondary structure-of proteins
34. Enzyme thermoinactivation in anhydrous organic solvents
35. Minimizing protein inactivation
36. The stabilization and encapsulation of human growth hormone into biodegradable microspheres
37. Analysis of polypeptides and proteins
38. Analytical methods for the assessment of protein formulations and delivery systems
39. Characterization of poly(glycolide-co-D,L-lactide)/poly (D,L-lactide) microspheres for controlled release of GMCSF
40. Factors affecting the in vitro release of recombinant human interferongamma (rhIFN-gamma) from PLGA microspheres
41. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes
42. Revisiting PLA/PLGA microspheres: An analysis of their potential in parenteral vaccination
43. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation
44. Controlled release of albumin from biodegradable poly(D,L-lactide) cylinders
45. Something new in the field of PLA/GA bioresorbable polymers?
46. Characterization of the initial burst drug release from poly(D,L-lactide-co-glycolide) microspheres II: Alterations in surface permeability implicated in cessation of burst release
47. The state of water in drug decomposition in the moist solid state: Description and modelling
48. The role of moisture in protein stability
49. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state
50. Rational design of stable protein formulations: Some practical advice
51. Solid-phase aggregation of proteins under pharmaceutically relevant conditions
52. Moisture-induced aggregation of lyophilized proteins in the solid state
53. Aggregation of a lyophilized pharmaceutical protein, recombinant human albumin: Effect of moisture and stabilization by excipients
54. Slow-release tetanus vaccine
55. Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro
56. 31P NMR spectroscopy
57. Non-invasive in vivo characterization of release processes in biodegradable polymers by low-frequency electron paramagnetic resonance spectroscopy
58. Monitoring microviscosity and microacidity of the albumin microenvironment inside degrading microparticles from poly(lactide-co-glycolide) (PLG) or ABA-triblock polymers containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethyleneoxide) B blocks
59. An acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins
60. pH and osmotic pressure inside biodegradable microspheres during erosion
61. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres
62. Development of poly (D,L-lactide-co-glycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis
63. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect
64. Correlation of measured microclimate pH with the stability of BSA encapsulated in PLGA microspheres
65. Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres
66. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles
67. Stabilization of vinca alkaloids encapsulated in poly(lactide-co-glycolide) microspheres
68. Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: Mechanism of stabilization by basic additives
69. Stabilization and controlled release of bovine serum albumin encapsulated in poly(D, L-lactide) and poly(ethylene glycol) microsphere blends
70. Protein adsorption and materials biocompatibility: A tutorial review and suggested hypotheses
71. Adsorption of proteins at solid-liquid interfaces
72. Factors affecting protein interaction at sorbent interfaces
73. Adsorption of serum albumin to thin films of poly(lactide-co-glycolide)
74. Stability and release of bovine serum albumin encapsulated within poly(D,L-lactide-co-glycolide) microparticles
75. Serum albumin
76. 2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants
77. Use of infrared spectroscopy to assess secondary structure of human growth hormone within biodegradable microspheres
78. On the structural preservation of recombinant human growth hormone in a dried film of a synthetic biodegradable polymer
79. FTIR characterization of the secondary structure of proteins encapsulated within PLGA microspheres
80. Stabilization of protein structure by solvent additives
81. In vivo characterization of sustained-release formulations of human growth hormone
82. A large-scale process to produce microencapsulated proteins
83. Stabilization of nerve growth factor during microencapsulation and release from microspheres
84. Effects of metal salts on poly(DL-lactide-co-glycolide) polymer hydrolysis
85. Water sorption and solid-state stability of proteins
86. Formaldehyde-mediated aggregation of protein antigens: Comparison of formalinized and untreated model antigens
87. Application of infrared spectroscopy to development of stable lyophilized protein formulations
88. Moisture-induced aggregation of lyophilized insulin
89. The secondary structure and aggregation of lyophilized tetanus toxoid
90. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro
91. Controlled release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: Influence of molecular weight and copolymer ratio of polymer
92. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid
93. Stabilization of vaccine antigens encapsulated in PLGA microspheres
94. Degradation and protein release properties of microspheres prepared from biodegradable poly(lactide-co-glycolide) and ABA triblock copolymers: Influence of buffer media on polymer erosion and bovine serum albumin release
95. The effect of a water/organic solvent interface on the structural stability of lysozyme
96. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres
97. Microencapsulation of human growth hormone within biodegradable polyester microspheres: Protein aggregation stability and incomplete release mechanism
98. Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen
99. Strategies for the stabilization of tetanus toxoid toward the development of a single-dose tetanus vaccine
100. Stabilization of tetanus toxoid in poly(D,L-lactic-co-glycolic acid) microspheres for the controlled release of antigen
101. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives
102. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle
103. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres
104. Microencapsulation of rh-erythropoietin, using biodegradable poly(D,L-lactide-co-glycolide): Protein stability and the effects of stabilizing excipients
105. Stability and controlled release of enzymes encapsulated in injectable poly(lactid-co-glycolide) cylindrical implants
106. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems